| Assay Method Information | |
| | Fluorescence Polarization Dose Response Assay for TR3-Based Bcl-B Inhibitors |
| Description: | Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG) Source Affiliation: Sanford-Burnham Medical Research Institute (SBMRI, San Diego, CA). Network: NIH Molecular Libraries Screening Centers Network (MLSCN) Grant Number: XO1 MH077632-01 Assay Provider: Dr. John C. Reed, Sanford-Burnham Medical Research Institute This dose response assay is developed and performed for the purpose of confirming hits originally identified in Fluorescence Polarization Screen Assay for Bcl-B Phenotype Converters (AID 1240). Bcl-B is an anti-apoptotic member of the Bcl-2 family that is prominently expressed in plasma and multiple myeloma cells. TR3 (NR4A1; HMR; NP10; GFRP1; NAK1; NUR77; NGFIB) is an orphan member of the steroid/thyroid/retinoid nuclear receptor superfamily that translocates from cellular nuclei to mitochondria upon exposure to various pro-apoptotic stimuli. At mitochondria, TR3 binds to Bcl-B and converts it into a pro-apoptotic protein. A specific 9-amino |
| Affinity data for this assay | |
|---|---|
| If you find an error in this entry please send us an E-mail | |